reports
NewtekOne, Inc. Declares Dividend on Series B Preferred Shares
NewtekOne, Inc. Declares Dividend on Series B Preferred Shares BOCA RATON, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) -- (“the Company”) (NASDAQ: NEWT) has declared a dividend on the Company’s outstanding 8.500% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series B (the “Preferred Shares”) in the amount of $21.25 per Preferred Share, or $0.53125 per depositary share, which is equivalent to 1/40th of the dividend on the Preferred Shares, payable on January 1, 2026 to holders of record as of December 22, 2025. About NewtekOne, Inc. , Your Business Solutions Company®, is a financi...
NewtekOne, Inc. Declares a Quarterly Dividend of $0.19 per Common Shar...
NewtekOne, Inc. Declares a Quarterly Dividend of $0.19 per Common Share BOCA RATON, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) -- (“the Company”) (NASDAQ: NEWT) announced that its Board of Directors declared a quarterly cash dividend of $0.19 per share on the outstanding common stock of NewtekOne. The dividend is payable on January 2, 2026, to shareholders of record as of December 22, 2025. Note Regarding Dividend Payments Amount and timing of dividends, if any, remain subject to the discretion of the Company's Board of Directors. About NewtekOne, Inc. , Your Business Solutions Company®, i...
Corcept Therapeutics Inc: 4 directors
Four Directors at Corcept Therapeutics Inc sold/sold after exercising options 85,000 shares at between 79.525USD and 80.076USD. The significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades ...
NewtekOne, Inc. Commences Exchange Offer for 2026 Notes
NewtekOne, Inc. Commences Exchange Offer for 2026 Notes BOCA RATON, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- NewtekOne, Inc. (“NewtekOne” or “Company”) (NASDAQ: NEWT) today announced the commencement of an offer to exchange (the “Exchange Offer”) any and all of its outstanding 5.50% Notes due 2026 (the “Old Notes”) for an equal principal amount of newly issued 8.50% Fixed Rate Senior Notes due 2031 (the “New Notes”). The Exchange Offer is being made pursuant to a registration statement on Form S-4 filed with the Securities and Exchange Commission (the “SEC”). As of December 1, 2025, $95.0...
NewtekOne, Inc. Announces Investor/Analyst Day and Provides 4Q25 Updat...
NewtekOne, Inc. Announces Investor/Analyst Day and Provides 4Q25 Update BOCA RATON, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- NewtekOne, Inc. (the “Company” or “NewtekOne”) (NASDAQ: NEWT) is pleased to announce the following updates for its fourth quarter ending December 31, 2025 (“4Q25”). NewtekOne anticipates launching this month a securitization and sale of rated notes backed by alternative loan program (“ALP”) loans. The securitization is anticipated to be the Company’s largest ever, its fourth securitization of ALP loans, and its 17th overall. This securitization will be the Company’s...
First Mining Gold Corp: 1 director
A director at First Mining Gold Corp bought 859,500 shares at 0.332CAD and the significance rating of the trade was 46/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Axsome Therapeutics to Participate in Upcoming Investor Conferences NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in December: Piper Sandler 37th Annual Healthcare Conference Fireside Chat: Wednesday, December 3, 2025, at 4:00 p.m. ET in New York, NY BofA Securities CNS Therapeutics Virtual Conference 2025 Fireside Chat: Monday, December 8, 2025, at 11:40...
- Jonathan Moreland
LNG CHENIERE ENERGY INC.
WM WASTE MANAGEMENT INC.
VRSK VERISK ANALYTICS INC
SLGN SILGAN HOLDINGS INC.
SFNC SIMMONS FIRST NATIONAL CORPORATION CLASS A
OHI OMEGA HEALTHCARE INVESTORS INC.
NCLH NORWEGIAN CRUISE LINE HOLDINGS LTD.
NBTB NBT BANCORP INC.
MTDR MATADOR RESOURCES COMPANY
MNRO MONRO INC
JBLU JETBLUE AIRWAYS CORPORATION
GBCI GLACIER BANCORP INC.
FISV FISERV INC.
FFIN FIRST FINANCIAL BANKSHARES INC
DENN DENNY'S CORPORATION
CNS COHEN & STEERS INC.
AMT AMERICAN TOWER CORPORATION
ASA ASA
NEWT NEWTEK BUSINESS SERVICES INC.
NCBS NICOLET BANKSHARES INC
RLMD RELMADA THERAPEUTICS
URE UR-ENERGY
KMI KINDER MORGAN INC CLASS P
MSM MSC INDUSTRIAL DIRECT CO. INC. CLASS A
NSC NORFOLK SOUTHERN CORPORATION
AJG ARTHUR J. GALLAGHER & CO.
WINA WINMARK CORP.
FND FLOOR & DECOR HOLDINGS INC. CLASS A
BX THE BLACKSTONE GROUP L.P.
MBIN MERCHANTS BANCORP
OBNK ORIGIN BANCORP
OSPN ONESPAN
FUSB FIRST US BANCSHARES INC
AVO MISSION PRODUCE
UTZ UTZ BRANDS INC (A)
OPCH OPTION CARE HEALTH INC
INTA INTAPP INC
CLVT CLARIVATE PLC
NVCT NUVECTIS PHARMA INC
BPRN BANK OF PRINCETON
GTE GRAN TIERRA ENERGY INC.
NCDL NUVEEN CHURCHILL DIRECT LENDING CORP
GAM GENERAL DE ALQUILER DE MAQUINARIA
LAW CS DISCO INC
GF THE NEW GERMANY FUND
ASST INC.
ASSET ENTITIES INC.
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positiv...
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABAA α2,3 receptor positive allosteric modulator Deepens Axsome’s broad and innovative neuroscience portfolio with a synergistic early-stage program for epilepsy NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has ente...
Newtek Merchant Solutions Hires Justine Martin as Chief Revenue Office...
Newtek Merchant Solutions Hires Justine Martin as Chief Revenue Officer BOCA RATON, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- NewtekOne, Inc. (“NewtekOne” or “Company”) (NASDAQ: NEWT) announced that its wholly owned subsidiary, Newtek Merchant Solutions, LLC (“NMS”), has hired Justine Martin as Chief Revenue Officer. In addition to teaching, training, and mentoring staff of NMS, Ms. Martin will focus on improving integration between the Company’s payments, banking, and lending functions. Ms. Martin will report to Barry Sloane, NMS’ Chief Executive Officer, and Michael Gleason, President and...
- Jonathan Moreland
USNA USANA HEALTH SCIENCES INC.
SLGN SILGAN HOLDINGS INC.
SFNC SIMMONS FIRST NATIONAL CORPORATION CLASS A
MTDR MATADOR RESOURCES COMPANY
MOFG MIDWESTONE FINANCIAL GROUP
FISV FISERV INC.
FFIN FIRST FINANCIAL BANKSHARES INC
ARCC ARES CAPITAL CORPORATION
ASA ASA
NEWT NEWTEK BUSINESS SERVICES INC.
NCBS NICOLET BANKSHARES INC
KMI KINDER MORGAN INC CLASS P
MSM MSC INDUSTRIAL DIRECT CO. INC. CLASS A
AJG ARTHUR J. GALLAGHER & CO.
FND FLOOR & DECOR HOLDINGS INC. CLASS A
MBIN MERCHANTS BANCORP
CLVT CLARIVATE PLC
GF THE NEW GERMANY FUND
INC.
Axsome Therapeutics Reports Third Quarter 2025 Financial Results and P...
Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update Total 3Q 2025 net product revenue of $171.0 million, representing 63% year-over-year growth AUVELITY® 3Q 2025 net product sales of $136.1 million, representing 69% year-over-year growth SUNOSI® 3Q 2025 net product revenue of $32.8 million, representing 35% year-over-year growth SYMBRAVO® 3Q 2025 net product sales of $2.1 million sNDA for AXS-05 in Alzheimer’s disease agitation submitted to the FDA Company to host conference call today at 8:00 AM Eastern NEW YORK, Nov. 03, 2025 (GLOBE NEWSWI...
NewtekOne, Inc. Reports 3Q25 and Year-to-Date 2025 Basic and Diluted E...
NewtekOne, Inc. Reports 3Q25 and Year-to-Date 2025 Basic and Diluted EPS of $0.68 and $0.67 and $1.57 and $1.54 Year-over-Year Quarterly and Year-to-Date Diluted EPS Growth Approximate 49% and 22% BOCA RATON, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- NewtekOne, Inc. (the "Company") (Nasdaq: NEWT) reports its financial and operating results for the three and nine month periods ended September 30, 2025. Financial Highlights for the three and nine months ended September 30, 2025: For the three months ended September 30, 2025 ("3Q25"), basic and diluted earnings per share ("EPS") were $0.68...
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Axsome Therapeutics to Participate in Upcoming Investor Conferences NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in November: 2025 Truist Securities BioPharma Symposium Fireside Chat: Thursday, November 6, 2025, at 9:50 a.m. ET in New York, NY Guggenheim 2nd Annual Healthcare Innovation ConferenceFireside Chat: Monday, November 10, 2025, at 11:00 a.m. ET i...
Axsome Therapeutics Recognizes Mental Illness Awareness Week Along wit...
Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it is recognizing Mental Illness Awareness Week (MIAW) alongside the national mental health advocacy community including the National Alliance on Mental Illness (NAMI). This year’s theme for MIAW is “Building Community: Supporting Mental Well-being Together,” to highlight the import...
NewtekOne, Inc. to Report Third Quarter 2025 Results and Host a Confer...
NewtekOne, Inc. to Report Third Quarter 2025 Results and Host a Conference Call on Wednesday, October 29, 2025 BOCA RATON, Fla., Oct. 08, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: NEWT) will report its third quarter 2025 financial results after the market closes on Wednesday, October 29, 2025. A conference call to discuss these results will be hosted by Barry Sloane, Chief Executive Officer and Frank DeMaria, Chief Financial Officer of NewtekOne at 4:30 pm ET on Wednesday, October 29, 2025. Please note, to receive a dial-in number for the conference call or to listen to the webc...
Axsome Therapeutics to Report Third Quarter 2025 Financial Results on ...
Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3 NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the third quarter of 2025 on Monday, November 3, 2025, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. To participate in the live...
Newtek Merchant Solutions Obtains Term Facility and Line of Credit fro...
Newtek Merchant Solutions Obtains Term Facility and Line of Credit from Goldman Sachs Alternatives BOCA RATON, Fla., Sept. 30, 2025 (GLOBE NEWSWIRE) -- NewtekOne, Inc. (“NewtekOne” or “Company”) (NASDAQ: NEWT) announced that its wholly owned subsidiary, Newtek Merchant Solutions, LLC (“NMS”), has refinanced its term debt facility and revolving line of credit. Private Credit at Goldman Sachs Alternatives is providing NMS with a $90 million term loan facility and a $5 million line of credit. A portion of the proceeds funded the full repayment of NMS’s approximately $30 million of outstandin...
NewtekOne, Inc. Declares a Quarterly Dividend of $0.19 per Share
NewtekOne, Inc. Declares a Quarterly Dividend of $0.19 per Share BOCA RATON, Fla., Sept. 30, 2025 (GLOBE NEWSWIRE) -- (“the Company”) (NASDAQ: NEWT) announced that its Board of Directors declared a quarterly cash dividend of $0.19 per share on the outstanding common stock of NewtekOne. The dividend is payable on October 24, 2025, to shareholders of record as of October 14, 2025. Note Regarding Dividend Payments Amount and timing of dividends, if any, remain subject to the discretion of the Company's Board of Directors. About NewtekOne, Inc. , Your Business Solutions C...
NewtekOne, Inc. Declares Dividend on Series B Preferred Shares
NewtekOne, Inc. Declares Dividend on Series B Preferred Shares BOCA RATON, Fla., Sept. 29, 2025 (GLOBE NEWSWIRE) -- (“the Company”) (NASDAQ: NEWT) has declared a dividend on the Company’s outstanding 8.500% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series B (the “Preferred Shares”) in the amount of $9.44 per Preferred Share, or $0.2361 per depositary share, which is equivalent to 1/40th of the dividend on the Preferred Shares, payable on October 1, 2025 to holders of record as of September 29, 2025. This initial dividend payment on the Preferred Shares is pro-rated for t...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.